Syneos Health has acquired technology-enabled clinical trial recruitment and retention company, StudyKIK, to enhance its ability to offer technology and insight-driven solutions.
Customer benefits comprise expedited subject enrolment and retention, wide patient population-centred insights, better site, sponsor and physician experiences and lowered subject burden.
Established in 2014 as an international network of patient-centred communities, StudyKIK and its technology platform showed enhanced quality and quicker enrolment timelines in some clinical trials by up to 94% and lowered enrolment start-up times by up to 75%.
Furthermore, StudyKIK offers eConsent, telemedicine video calling, phone pre-qualifications and patient retention application solutions.
The firm handles more than 1,000 indication-oriented patient community groups and has enrolled over 5,400 protocols backing more than 3,800 research centres worldwide.
The platform comprises more than six million subjects through social media, accelerating access to patients who would not have otherwise taken part in clinical trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
StudyKIK complements the patient, centre and community strategic focus of Syneos Health. It also adds new scale and expertise to boost the subject journey while streamlining data science and behavioural insights to back product marketing.
The deal further strengthens Syneos Health’s patient-direct, technology-enabled solutions portfolio supplementing the latest takeover of Illingworth Research Group and technology collaborations with Ride Health, Science37 and Medable.
Syneos Health CEO Alistair Macdonald said: “StudyKIK’s patient-first focus, combined with their innovative enterprise platform, helps to advance our goal of bringing best-of-breed insights and technology-enabled solutions to biopharma customers, sites and patients.
“Together we’ll accelerate product development by improving stakeholder experiences, realising efficiencies in patient recruitment, engagement, improved access and diversity.”
Syneos Health is a completely integrated biopharmaceutical solutions organisation and the transaction is strategic to developing its Dynamic Assembly network.
Dynamic Assembly is an open ecosystem of data and technology partners created to tactically address the nuances of user engagements.
In March, Syneos Health reached a strategic collaboration with Science 37 to enable the delivery of decentralised clinical trials.